摘要
目的观察头孢西丁钠、奥硝唑联合妇康口服液治疗急性盆腔炎的临床疗效。方法将医院收治的急性盆腔炎(湿热蕴结证)患者85例随机分为对照组(n=42)和治疗组(n=43),对照组患者给予头孢西丁钠联合奥硝唑静脉滴注,治疗组患者在对照组治疗基础上加用妇康口服液,连续治疗2周。结果治疗后,治疗组患者中医症状分级量化积分、盆腔超声检查结果(积液深度、盆腔炎性包块直径)、感染指标(除体温外)水平、特异性生物标志物水平、临床症状改善时间及住院时间均显著优于对照组(P<0.05);两组患者治疗期间不良反应发生率相当(7.14%比9.30%,P>0.05);治疗组总有效率为95.35%,显著高于对照组的80.95%(χ2=4.242,P=0.039<0.05)。结论头孢西丁钠、奥硝唑联合妇康口服液治疗急性盆腔炎能显著改善临床症状,改善感染性指标和特异性生物标志物水平,可提高临床疗效。
Objective To observe the clinical efficacy of cefoxitin sodium and ornidazole combined with Fukang Oral Liquid in the treat-ment of acute pelvic inflammatory disease.Methods Totally 85 patients with acute pelvic inflammatory disease(pattern of damp-heat brewing and binding)were randomly divided into the control group(n=42)and the treatment group(n=43).The control group was treated with intravenous infusion of cefoxitin sodium and ornidazole,on this basis,the treat ment group was treated with Fukang Oral Liquid.The two groups were treated for 2 weeks.Results After treatment,the TCM symptom quantified scores,ultrasonic examination of pelvic cavity results(pelvic effusion depth and pelvic inflammatory mass diameter),the level of infectious indexes(in addition to body tempera-ture),the level of specific biomarkers,clinical symptoms improvement time and hospitalization time in the treatment group were signifi-cantly better than those in th econtrol group(P<0.05).There was no significant difference in the incidence rate of adverse reactions between the two groups during the treatment(7.14%vs.9.30%,P>0.05).The total effective rate ofthe treatment group was 95.35%,which was significantly higher than 80.95%of the control group(χ2=4.242,P=0.039<0.05).Conclusion Cefoxitin sodium and ornidazole combined with Fukang Oral Liquid in the treatment of acute pelvic inflammatory disease can significantly improve the clinical symptoms,the levels of infectious indexes and specific biomarkers,which can significantly improve the clinical effect.
作者
邓黎
姜静
Deng Li;Jiang Jing(Department of Gynaecology,The Second People′s Hospital of Yibin,Yibin,Sichuan,China 644000)
出处
《中国药业》
CAS
2018年第6期69-71,共3页
China Pharmaceuticals
关键词
头孢西丁钠
奥硝唑
妇康口服液
急性盆腔炎
临床疗效
cefoxitin sodium
ornidazole
Fukang Oral Liquid
acute pelvic inflammatory disease
clinical effect
